Yazar "Bilgin, Burak" için listeleme
-
The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
Kılıçkap, Saadettin; Ölmez, Ömer Fatih; Cicin, İrfan; Demirci, Umut; Alan, O.; Çabuk, Devrim; Sakalar, Teoman; Tatlı, Ali Murat; Buğdaycı, F. Başol; Eralp, Yeşim; Uysal, Mükremin; Demirkazik, Ahmet; Bilgin, Burak; Yıldız, Birol; Karaağaç, Mustafa; Okutur, Kerem; Sakin, Ayşegül (Oxford University Press, 2018)… -
Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): A prospective, multicentre study in 69 neonatal intensive care units
Baş, Ahmet Yağmur; Demirel, Nihal; Koç, Esin; Ulubaş Işık, Dilek; Hirfanoğlu, İbrahim Murat; Tunç, Turan; Sarı, Fatma Nur; Karatekin, Güner; Köklü, Esad; Altunhan, Hüseyin; Turgut, Hatice; Narter, Fatma; Tarakçı, Nuriye; Tekgündüz, Kadir Şerafettin; Özkiraz, Servet; Aydemir, Cumhur; Özdemir, Ahmet; Çetinkaya, Bilin; Kazancı, Ebru; Taştekin, Ayhan; Calkavur, Şebnem; Özyurt, Banu Mutlu; Demirelli, Yaşar; Asker, Hüseyin Selim; Mutlu, Birgül; Uygur, Özgün; Özkan, Hilal; Armangil, Didem; Özlü, Ferda; Mert, Mustafa Kurthan; Ergin, Hacer; Özcan, Beyza; Baş, Evrim Kiray; Okulu, Emel; Acunaş, Betül; Çelik, Ülker; Uslu, Sait İlker; Mutlu, Mehmet; Demir, Nihat; Eroğlu, Funda; Gökmen, Zeynel; Beken, Serdar; Bayraktar, Bilge Tanyeri; Hakan, Nilay; Küçüktaşçı, Kazım; Orman, Ayşen; Cömert, Serdar; Ertuğrul, Sabahattin; Üstün, Nuran; Şahin, Özlem; Terek, Demet; Kale, Yusuf; Konak, Murat; Yurttutan, Sadık; Aydemir, Özge; Zenciroğlu, Ayşegül; Sarıcı, Dilek; Güzoğlu, Nilüfer; Hamilcikan, Şahin; Gürsoy, Tuğba; Tüzün, Funda; Ors, Rahmi; Arslan, Selda; Akdağ, Arzu; Memişoğlu, Aslı; Yaşa, Beril; Hekimoğlu, Berna; Turan, Özden; Aylanç, Hakan; Takçı, Şahin; Çelik, Tolga; Şahin, Suzan; Kılıç, İlknur; Kara, Caner; Tunay, Zuhal Özen; Çelik, Gökhan; Gözen, İbrahim; Satırtav, Günhal; Polat, Nihat; Oral, Ayşe Yeşim; Tokgöz, Mine; Keleş, Sadullah; Bilgin, Burak; Ugurbaş, Şilay Cantürk; Karaca, Çağatay; Keşkek, Nedime Şahinoğlu; Ekinci, Dilbade Yıldız; Balcı, Özlem; Altan, Emir Volkan; Bakbak, Sevda; Ceylan, Nihan Aksu; Kimyon, Sabit; Alyamaç, Günay; Türe, Gamze; Yıldız, Meral; Çalış, Feyza; Sızmaz, Selçuk; Sükgen, Emine; Çetin, Ebru Nevin; Özçimen, Muammer; Tiryaki Demir, Semra; Atila, Huban; Özal, Altan; Tufaner, Gökhan; Eski Yücel, Özlem; Kola, Mehmet; Seven, Erbil; Özdek, Şengül; Durukan, Ali Hakan; Kal, Ali; Çelebi, Ali Rıza Cenk; Koytak, İbrahim Arif; Alacamlı, Göksu; Esme, Arif; Çatak, Onur; Perente, İrfan; Şahin, Alparslan; Ardagil Akçakaya, Aylin; Kiray, Gülünay; Nalcacı, Serhat; Aksoy, Ümit; Bakbak, Berker; Çömez, Ayşegül; Gürsoy, Hüseyin; Kabataş, Emrah Utku; Petriçli, İkbal Seza; Yumuşak, Mehmet Erhan; Kırgız, Ahmet; Uludağ, Günay; Yaman, Aylin; Dadacı, Zeynep; Karataş, Ali; Çeliker, Hande; Cebeci, Zafer; Esenülkü, Mahmut Cenap; Akkoyun, İmren; Ersan, İsmail; Demir, Selim; Kadayıfçılar, Sibel; Ünsal, Ayşe İpek Akyüz; Hocaoğlu, Mümin (BMJ Publishing Group, 2018)Background To evaluate the prevalence, risk factors and treatment of retinopathy of prematurity (ROP) in Turkey and to establish screening criteria for this condition. Methods A prospective cohort study (TR-ROP) was performed ... -
Predictive factor for lymph node metastasis in non-metastatic colorectal adenocarcinomas
Karcı, Ebru; Ürün, Yüksel; Köksoy, Elif Berna; Uçar, Gökhan; Bilgin, Burak; Yekedüz, Emre; Arslan, Çağatay; Alkan, Ali; Dede, İsa; Tuncay, Gülseren; Hocazade, Cemil; Yıldırım Özdemir, Nuriye; Şendur, Mehmet Ali Nahit; Utkan, Güngör; Yalçın, Bülent; Akbulut, Hakan (Kare Publishing, 2022)Objectives: To evaluate the predictive factors of lymph node involvement in non-metastatic colorectal adenocarcinomas (nmCRC). Methods: A total of 453 patients diagnosed with nmCRC were analyzed regarding T stage, ... -
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Gürsoy, Pınar; Tatlı, Ali Murat; Erdem, Dilek; Göker, Erdem; Çelik, Emir; Demirci, Nebi Serkan; Sakin, Abdullah; Atçı, Muhammed Mustafa; Bayram, Ertuğrul; Akın Telli, Tuğba; Bilgin, Burak; Bilici, Ahmet (Springer, 2023)Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Açıkgöz, Özgür; Sezer, Ahmet; Gürbüz, Mustafa; Ak, Naziye; Yücel, Şebnem; Ayhan, Murat; Erol, Cihan; Demirkıran, Aykut; Mandel, Nil Molinas; Shbair, Abdallah; Gökmen, İvo; Başoğlu, Tuğba; Paydaş, Semra; Demiray, Atike Gökçen; İriağaç, Yakup; Şakalar, Teoman; Zeynelgil, Esra; Tatlı, Ali Murat; Bahçeci, Aykut; Güven, Deniz Can; Caner, Burcu; Can, Alper; Gülmez, Ahmet; Karakaş, Yusuf; Yalçın, Bülent; Demirkazık, Ahmet; Bilici, Ahmet; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Springer, 2022)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ... -
The real-life efficacy of the second line treatment strategy in advanced pancreas cancer
Hızal, Mutlu; Şendur, Mehmet Ali Nahit; Bilgin, Burak; Karcı Güner, Ebru; Akıncı, Muhammed Bülent; Ergün, Yakup; Esin, Ece; Köksoy, Elif Berna; Sezer, Ahmet; Özdemir, Nuriye; Öksüzoğlu, Berna; Yalçın, Bülent; Utkan, Güngör; Ürün, Yüksel (Turkiye Klinikleri, 2022)ABS TRACT Objective: Pancreatic cancer is one of the leading causes of cancer-related death. Despite the introduction of new therapeutic agents, survival rates remain low. Furthermore, few trials have evaluated the options ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ...